TY - JOUR T1 - State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now? JF - Anticancer Research JO - Anticancer Res SP - 3405 LP - 3412 DO - 10.21873/anticanres.13484 VL - 39 IS - 7 AU - RITA BALSANO AU - CHIARA TOMMASI AU - INGRID GARAJOVA Y1 - 2019/07/01 UR - http://ar.iiarjournals.org/content/39/7/3405.abstract N2 - The prognosis of metastatic pancreatic cancer remains poor despite the recent progress on modern chemotherapeutic regimens, such as FOLFIRINOX, gemcitabine and nab-paclitaxel. A better understanding of the altered signalling pathways and the importance of stroma and the immune environment in pancreatic cancer have led to the development of new clinical trials with promising results. In the present review, a general outline of current first- and second-line therapies is provided. Further, new therapeutic possibilities are reviewed, in particular EGFR and VEGF inhibitors, immunotherapy and PARP inhibitors. ER -